DrugPatentWatch Database Preview

R-pharm Us Llc Company Profile

« Back to Dashboard

What is the competitive landscape for R-PHARM US LLC, and what generic alternatives to R-PHARM US LLC drugs are available?

R-PHARM US LLC has one approved drug.

There are six US patents protecting R-PHARM US LLC drugs.

There are two hundred and eight patent family members on R-PHARM US LLC drugs in forty-five countries and one supplementary protection certificate in one country.

Summary for R-pharm Us Llc

International Patents:	208
US Patents:	6
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for R-pharm Us Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-002	Oct 16, 2007		RX	Yes	Yes	7,125,899*PED				Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007		RX	Yes	Yes	RE41911*PED				Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007		RX	Yes	Yes	6,670,384*PED				Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007		RX	Yes	Yes	7,125,899*PED				Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007		RX	Yes	Yes	7,312,237*PED				Y
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-002	Oct 16, 2007		RX	Yes	Yes	7,312,237*PED				Y

Expired US Patents for R-pharm Us Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-001	Oct 16, 2007	6,605,599
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;IV (INFUSION)	022065-002	Oct 16, 2007	6,605,599

Paragraph IV (Patent) Challenges for R-PHARM US LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	15 mg/vial and 45 mg/vial, single-use vials		2012-04-16

Non-Orange Book US Patents for R-pharm Us Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,598,215	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
6,576,651	Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
8,569,347	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
6,605,599	Epothilone derivatives
RE41893	Epothilone derivatives
RE40387	Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones

International Patents for R-pharm Us Llc Drugs

Country	Document Number	Estimated Expiration
Iceland	2882
South Africa	200305126
Japan	2007291121
South Africa	200306173
Bulgaria	108027
Poland	373727

Supplementary Protection Certificates for R-pharm Us Llc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1019389/01	Switzerland		PRODUCT NAME: IXABEPILONE; REGISTRATION NUMBER/DATE: SWISSMEDIC 58880 27.02.2009

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• R-pharm Us Llc